The change of serum vascular endothelial growth factor and matrix metalloproteinases-9 in proliferative hemangioma treated with propranolol.
- Author:
Zhong-Fang ZHAO
1
;
Ren-Rong LÜ
;
Ran HUO
;
Hong-Bing FU
;
Guang-Qi XU
Author Information
- Publication Type:Journal Article
- MeSH: Female; Hemangioma; blood; drug therapy; pathology; Humans; Infant; Male; Matrix Metalloproteinase 9; blood; Propranolol; therapeutic use; Serum; metabolism; Vascular Endothelial Growth Factor A; blood
- From: Chinese Journal of Plastic Surgery 2011;27(5):359-361
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the level of serum vascular endothelial growth factor, matrix metalloproteinases-9 in the proliferative hemangioma before and after propranolol treatment.
METHODSThe serum VEGF, MMP-9 was detected with ELISA assay before treatment and after 4 weeks and 8 weeks of propranolol treatment. The relationship between the serum VEGF, MMP-9 and the prognosis was analyzed.
RESULTSThe serum VEGF (295.4 +/- 158.1) pg/ml was high before treatment, then decreased after 4 weeks and 8 weeks of treatment (255.7 +/- 130.4) pg/ml, (224.2 +/- 120.6) pg/ml. The serum VEGF was significantly lower after 8 weeks of treatment (P < 0.05). The serum MMP-9 was also decreased after treatment, showing a positive relationship with VEGF.
CONCLUSIONSPropranolol can treat the proliferative hemangioma through decreasing the serum VEGF and MMP-9.
